For senior citizen’s who are suffering from Type 2 diabetes (T2D), for them managing sugar level is a major problem.
But for these elderly’s the new drugs launched last year to tackle this problem have shown a good result. Boehringer Ingelheim and Eli Lilly and Company announced a new data that reinforce the efficacy and tolerability of linagliptin in people with T2D and liver disease, as well as Asian people with T2D aged 65 years or older. Linagliptin successfully shows a reduction in blood glucose level. These drugs come under the brand name Trajenta.
The data was recently announced during the 5th Asian Association for the Study of Diabetes (AASD) Annual Scientific meeting.
An estimated of 371 million people worldwide have Type 1 and T2D. T2D is the most common type, accounting to 90% of all diabetes cases.
Commenting on the studies, professor Klaus Dugi, corporate senior vice president medicine, Boehringer Ingelheim, said, “The effects of the treatment on health in specific groups of people with T2D, such as elderly and those with liver disease, must be considered. However, there is a limited choice of treatment for those who have complications. The findings support linagliptin’s safety and efficacy in these populations with T2D, and confirm that linagliptin is a good option.”